Physician profile
Morgan Thomas
NPI 1992271134
$2,964.33
in general payments reported to CMS, 2019-2025
17 companies · $905 in 2025
The $905 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2023: $428 · 2024: $1,290 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.10 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.01 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $400.19 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $377.53 | 2024-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $316.16 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.10 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $157.10 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $96.52 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $69.49 | 2021 | |
| Collegium Pharmaceutical, INC. | $53.36 | 2025 | Jornay Pm |
| Lundbeck LLC | $51.08 | 2024 | Rexulti |
| Alkermes, INC. | $50.98 | 2021-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $50.64 | 2021-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $49.81 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.93 | 2021-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $41.42 | 2021-2024 | Ingrezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $32.22 | 2025 | Onyda Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.79 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.